Search

Your search keyword '"A., Matrone"' showing total 108 results
Start Over Author "A., Matrone" Publisher american association for cancer research (aacr)
108 results on '"A., Matrone"'

1. Supplementary Table 1 from EPHA2 Is a Predictive Biomarker of Resistance and a Potential Therapeutic Target for Improving Antiepidermal Growth Factor Receptor Therapy in Colorectal Cancer

Author

Martini, Giulia, primary, Cardone, Claudia, primary, Vitiello, Pietro Paolo, primary, Belli, Valentina, primary, Napolitano, Stefania, primary, Troiani, Teresa, primary, Ciardiello, Davide, primary, Della Corte, Carminia Maria, primary, Morgillo, Floriana, primary, Matrone, Nunzia, primary, Sforza, Vincenzo, primary, Papaccio, Gianpaolo, primary, Desiderio, Vincenzo, primary, Paul, Mariel C., primary, Moreno-Viedma, Veronica, primary, Normanno, Nicola, primary, Rachiglio, Anna Maria, primary, Tirino, Virginia, primary, Maiello, Evaristo, primary, Latiano, Tiziana Pia, primary, Rizzi, Daniele, primary, Signoriello, Giuseppe, primary, Sibilia, Maria, primary, Ciardiello, Fortunato, primary, and Martinelli, Erika, primary

Published
2023
Full Text
View/download PDF

2. Supplementary Table 2 from EPHA2 Is a Predictive Biomarker of Resistance and a Potential Therapeutic Target for Improving Antiepidermal Growth Factor Receptor Therapy in Colorectal Cancer

Author

Martini, Giulia, primary, Cardone, Claudia, primary, Vitiello, Pietro Paolo, primary, Belli, Valentina, primary, Napolitano, Stefania, primary, Troiani, Teresa, primary, Ciardiello, Davide, primary, Della Corte, Carminia Maria, primary, Morgillo, Floriana, primary, Matrone, Nunzia, primary, Sforza, Vincenzo, primary, Papaccio, Gianpaolo, primary, Desiderio, Vincenzo, primary, Paul, Mariel C., primary, Moreno-Viedma, Veronica, primary, Normanno, Nicola, primary, Rachiglio, Anna Maria, primary, Tirino, Virginia, primary, Maiello, Evaristo, primary, Latiano, Tiziana Pia, primary, Rizzi, Daniele, primary, Signoriello, Giuseppe, primary, Sibilia, Maria, primary, Ciardiello, Fortunato, primary, and Martinelli, Erika, primary

Published
2023
Full Text
View/download PDF

3. Data from EPHA2 Is a Predictive Biomarker of Resistance and a Potential Therapeutic Target for Improving Antiepidermal Growth Factor Receptor Therapy in Colorectal Cancer

Author

Martini, Giulia, primary, Cardone, Claudia, primary, Vitiello, Pietro Paolo, primary, Belli, Valentina, primary, Napolitano, Stefania, primary, Troiani, Teresa, primary, Ciardiello, Davide, primary, Della Corte, Carminia Maria, primary, Morgillo, Floriana, primary, Matrone, Nunzia, primary, Sforza, Vincenzo, primary, Papaccio, Gianpaolo, primary, Desiderio, Vincenzo, primary, Paul, Mariel C., primary, Moreno-Viedma, Veronica, primary, Normanno, Nicola, primary, Rachiglio, Anna Maria, primary, Tirino, Virginia, primary, Maiello, Evaristo, primary, Latiano, Tiziana Pia, primary, Rizzi, Daniele, primary, Signoriello, Giuseppe, primary, Sibilia, Maria, primary, Ciardiello, Fortunato, primary, and Martinelli, Erika, primary

Published
2023
Full Text
View/download PDF

4. Supplementary Figure 2 from EPHA2 Is a Predictive Biomarker of Resistance and a Potential Therapeutic Target for Improving Antiepidermal Growth Factor Receptor Therapy in Colorectal Cancer

Author

Martini, Giulia, primary, Cardone, Claudia, primary, Vitiello, Pietro Paolo, primary, Belli, Valentina, primary, Napolitano, Stefania, primary, Troiani, Teresa, primary, Ciardiello, Davide, primary, Della Corte, Carminia Maria, primary, Morgillo, Floriana, primary, Matrone, Nunzia, primary, Sforza, Vincenzo, primary, Papaccio, Gianpaolo, primary, Desiderio, Vincenzo, primary, Paul, Mariel C., primary, Moreno-Viedma, Veronica, primary, Normanno, Nicola, primary, Rachiglio, Anna Maria, primary, Tirino, Virginia, primary, Maiello, Evaristo, primary, Latiano, Tiziana Pia, primary, Rizzi, Daniele, primary, Signoriello, Giuseppe, primary, Sibilia, Maria, primary, Ciardiello, Fortunato, primary, and Martinelli, Erika, primary

Published
2023
Full Text
View/download PDF

5. Supplementary Materials and Methods from EPHA2 Is a Predictive Biomarker of Resistance and a Potential Therapeutic Target for Improving Antiepidermal Growth Factor Receptor Therapy in Colorectal Cancer

Author

Martini, Giulia, primary, Cardone, Claudia, primary, Vitiello, Pietro Paolo, primary, Belli, Valentina, primary, Napolitano, Stefania, primary, Troiani, Teresa, primary, Ciardiello, Davide, primary, Della Corte, Carminia Maria, primary, Morgillo, Floriana, primary, Matrone, Nunzia, primary, Sforza, Vincenzo, primary, Papaccio, Gianpaolo, primary, Desiderio, Vincenzo, primary, Paul, Mariel C., primary, Moreno-Viedma, Veronica, primary, Normanno, Nicola, primary, Rachiglio, Anna Maria, primary, Tirino, Virginia, primary, Maiello, Evaristo, primary, Latiano, Tiziana Pia, primary, Rizzi, Daniele, primary, Signoriello, Giuseppe, primary, Sibilia, Maria, primary, Ciardiello, Fortunato, primary, and Martinelli, Erika, primary

Published
2023
Full Text
View/download PDF

6. Supplementary Table 3 from EPHA2 Is a Predictive Biomarker of Resistance and a Potential Therapeutic Target for Improving Antiepidermal Growth Factor Receptor Therapy in Colorectal Cancer

Author

Martini, Giulia, primary, Cardone, Claudia, primary, Vitiello, Pietro Paolo, primary, Belli, Valentina, primary, Napolitano, Stefania, primary, Troiani, Teresa, primary, Ciardiello, Davide, primary, Della Corte, Carminia Maria, primary, Morgillo, Floriana, primary, Matrone, Nunzia, primary, Sforza, Vincenzo, primary, Papaccio, Gianpaolo, primary, Desiderio, Vincenzo, primary, Paul, Mariel C., primary, Moreno-Viedma, Veronica, primary, Normanno, Nicola, primary, Rachiglio, Anna Maria, primary, Tirino, Virginia, primary, Maiello, Evaristo, primary, Latiano, Tiziana Pia, primary, Rizzi, Daniele, primary, Signoriello, Giuseppe, primary, Sibilia, Maria, primary, Ciardiello, Fortunato, primary, and Martinelli, Erika, primary

Published
2023
Full Text
View/download PDF

7. Supplementary Figure 1 from EPHA2 Is a Predictive Biomarker of Resistance and a Potential Therapeutic Target for Improving Antiepidermal Growth Factor Receptor Therapy in Colorectal Cancer

Author

Martini, Giulia, primary, Cardone, Claudia, primary, Vitiello, Pietro Paolo, primary, Belli, Valentina, primary, Napolitano, Stefania, primary, Troiani, Teresa, primary, Ciardiello, Davide, primary, Della Corte, Carminia Maria, primary, Morgillo, Floriana, primary, Matrone, Nunzia, primary, Sforza, Vincenzo, primary, Papaccio, Gianpaolo, primary, Desiderio, Vincenzo, primary, Paul, Mariel C., primary, Moreno-Viedma, Veronica, primary, Normanno, Nicola, primary, Rachiglio, Anna Maria, primary, Tirino, Virginia, primary, Maiello, Evaristo, primary, Latiano, Tiziana Pia, primary, Rizzi, Daniele, primary, Signoriello, Giuseppe, primary, Sibilia, Maria, primary, Ciardiello, Fortunato, primary, and Martinelli, Erika, primary

Published
2023
Full Text
View/download PDF

8. Supplementary Table 3 from EPHA2 Is a Predictive Biomarker of Resistance and a Potential Therapeutic Target for Improving Antiepidermal Growth Factor Receptor Therapy in Colorectal Cancer

Author

Erika Martinelli, Fortunato Ciardiello, Maria Sibilia, Giuseppe Signoriello, Daniele Rizzi, Tiziana Pia Latiano, Evaristo Maiello, Virginia Tirino, Anna Maria Rachiglio, Nicola Normanno, Veronica Moreno-Viedma, Mariel C. Paul, Vincenzo Desiderio, Gianpaolo Papaccio, Vincenzo Sforza, Nunzia Matrone, Floriana Morgillo, Carminia Maria Della Corte, Davide Ciardiello, Teresa Troiani, Stefania Napolitano, Valentina Belli, Pietro Paolo Vitiello, Claudia Cardone, and Giulia Martini

Abstract

Supplementary Table 3: EPHA2 expression in tumor samples with HSCORE

Published
2023
Full Text
View/download PDF

9. Supplementary Figure 1 from EPHA2 Is a Predictive Biomarker of Resistance and a Potential Therapeutic Target for Improving Antiepidermal Growth Factor Receptor Therapy in Colorectal Cancer

Author

Erika Martinelli, Fortunato Ciardiello, Maria Sibilia, Giuseppe Signoriello, Daniele Rizzi, Tiziana Pia Latiano, Evaristo Maiello, Virginia Tirino, Anna Maria Rachiglio, Nicola Normanno, Veronica Moreno-Viedma, Mariel C. Paul, Vincenzo Desiderio, Gianpaolo Papaccio, Vincenzo Sforza, Nunzia Matrone, Floriana Morgillo, Carminia Maria Della Corte, Davide Ciardiello, Teresa Troiani, Stefania Napolitano, Valentina Belli, Pietro Paolo Vitiello, Claudia Cardone, and Giulia Martini

Abstract

Supplementary Figure 1. A: Phosphoarray analysis of SW48 and SW48-CR cell lines. B: Silencing of EPHA2 decreases the sensitivity to ALW-II-41-27 in HCT15 and SW48-CR cell lines.

Published
2023
Full Text
View/download PDF

10. Data from EPHA2 Is a Predictive Biomarker of Resistance and a Potential Therapeutic Target for Improving Antiepidermal Growth Factor Receptor Therapy in Colorectal Cancer

Author

Erika Martinelli, Fortunato Ciardiello, Maria Sibilia, Giuseppe Signoriello, Daniele Rizzi, Tiziana Pia Latiano, Evaristo Maiello, Virginia Tirino, Anna Maria Rachiglio, Nicola Normanno, Veronica Moreno-Viedma, Mariel C. Paul, Vincenzo Desiderio, Gianpaolo Papaccio, Vincenzo Sforza, Nunzia Matrone, Floriana Morgillo, Carminia Maria Della Corte, Davide Ciardiello, Teresa Troiani, Stefania Napolitano, Valentina Belli, Pietro Paolo Vitiello, Claudia Cardone, and Giulia Martini

Abstract

The EPHA2 tyrosine kinase receptor is implicated in tumor progression and targeted therapies resistance. We evaluated EPHA2 as a potential resistance marker to the antiepidermal growth factor receptor (EGFR) monoclonal antibody cetuximab in colorectal cancer. We studied activation of EPHA2 in a panel of human colorectal cancer cell lines sensitive or resistant to anti-EGFR drugs. The in vitro and in vivo effects of ALW-II-41-27 (an EPHA2 inhibitor) and/or cetuximab treatment were tested. Formalin-fixed paraffin-embedded tumor specimens from 82 RAS wild-type (WT) metastatic colorectal cancer patients treated with FOLFIRI + cetuximab as first-line therapy in the CAPRI-GOIM trial were assessed for EPHA2 expression by immunohistochemistry and correlated with treatment efficacy. EPHA2 was differentially activated in colorectal cancer cell lines. Combined treatment with ALW-II-41-27 plus cetuximab reverted primary and acquired resistance to cetuximab, causing cell growth inhibition, inducing apoptosis and cell-cycle G1–G2 arrest. In tumor xenograft models, upon progression to cetuximab, ALW-II-41-27 addition significantly inhibited tumor growth. EPHA2 protein expression was detected in 55 of 82 tumor samples, frequently expressed in less-differentiated and left-sided tumors. High levels of EPHA2 significantly correlated with worse progression-free survival [8.6 months; confidence interval (CI) 95%, 6.4–10.8; vs. 12.3 months; CI 95%, 10.4–14.2; P = 0.03] and with increased progression rate (29% vs. 9%, P = 0.02). A specific EPHA2 inhibitor reverts in vitro and in vivo primary and acquired resistance to anti-EGFR therapy. EPHA2 levels are significantly associated with worse outcome in patients treated with FOLFIRI + cetuximab. These results highlight EPHA2 as a potential therapeutic target in metastatic colorectal cancer.

Published
2023
Full Text
View/download PDF

11. Supplementary Figure 2 from EPHA2 Is a Predictive Biomarker of Resistance and a Potential Therapeutic Target for Improving Antiepidermal Growth Factor Receptor Therapy in Colorectal Cancer

Author

Erika Martinelli, Fortunato Ciardiello, Maria Sibilia, Giuseppe Signoriello, Daniele Rizzi, Tiziana Pia Latiano, Evaristo Maiello, Virginia Tirino, Anna Maria Rachiglio, Nicola Normanno, Veronica Moreno-Viedma, Mariel C. Paul, Vincenzo Desiderio, Gianpaolo Papaccio, Vincenzo Sforza, Nunzia Matrone, Floriana Morgillo, Carminia Maria Della Corte, Davide Ciardiello, Teresa Troiani, Stefania Napolitano, Valentina Belli, Pietro Paolo Vitiello, Claudia Cardone, and Giulia Martini

Abstract

Supplementary Figure 2. A-B: Synergistic anti-proliferative effects of the combination of ALW-II-41-27 and cetuximab.C: Effect of Epha2 gene knockdown on cetuximab sensitivity in HCT116 and LOVO cell lines. D: Effects of combination treatment with ALW-II-41-27 and cetuximab on induction of apoptosis. E: Cell cycle distribution for HCT15 and SW48-CR following treatment with ALW-II-41-27 and/or cetuximab for 24, 48 and 72 hrs at indicated doses. F: Effects of EPHA2 blockade alone and in combination with cetuximab on intracellular signalling pathways of cell proliferation and survival.

Published
2023
Full Text
View/download PDF

12. Supplementary Materials and Methods from EPHA2 Is a Predictive Biomarker of Resistance and a Potential Therapeutic Target for Improving Antiepidermal Growth Factor Receptor Therapy in Colorectal Cancer

Author

Erika Martinelli, Fortunato Ciardiello, Maria Sibilia, Giuseppe Signoriello, Daniele Rizzi, Tiziana Pia Latiano, Evaristo Maiello, Virginia Tirino, Anna Maria Rachiglio, Nicola Normanno, Veronica Moreno-Viedma, Mariel C. Paul, Vincenzo Desiderio, Gianpaolo Papaccio, Vincenzo Sforza, Nunzia Matrone, Floriana Morgillo, Carminia Maria Della Corte, Davide Ciardiello, Teresa Troiani, Stefania Napolitano, Valentina Belli, Pietro Paolo Vitiello, Claudia Cardone, and Giulia Martini

Abstract

Supplementary materials and methods

Published
2023
Full Text
View/download PDF

13. Supplementary Table 2 from EPHA2 Is a Predictive Biomarker of Resistance and a Potential Therapeutic Target for Improving Antiepidermal Growth Factor Receptor Therapy in Colorectal Cancer

Author

Erika Martinelli, Fortunato Ciardiello, Maria Sibilia, Giuseppe Signoriello, Daniele Rizzi, Tiziana Pia Latiano, Evaristo Maiello, Virginia Tirino, Anna Maria Rachiglio, Nicola Normanno, Veronica Moreno-Viedma, Mariel C. Paul, Vincenzo Desiderio, Gianpaolo Papaccio, Vincenzo Sforza, Nunzia Matrone, Floriana Morgillo, Carminia Maria Della Corte, Davide Ciardiello, Teresa Troiani, Stefania Napolitano, Valentina Belli, Pietro Paolo Vitiello, Claudia Cardone, and Giulia Martini

Abstract

Supplementary Table 2: EPHA2 expression in tumor samples of 82 RAS WT colorectal cancer patients from the GOIM-CAPRI trial

Published
2023
Full Text
View/download PDF

14. Supplementary Table 1 from EPHA2 Is a Predictive Biomarker of Resistance and a Potential Therapeutic Target for Improving Antiepidermal Growth Factor Receptor Therapy in Colorectal Cancer

Author

Erika Martinelli, Fortunato Ciardiello, Maria Sibilia, Giuseppe Signoriello, Daniele Rizzi, Tiziana Pia Latiano, Evaristo Maiello, Virginia Tirino, Anna Maria Rachiglio, Nicola Normanno, Veronica Moreno-Viedma, Mariel C. Paul, Vincenzo Desiderio, Gianpaolo Papaccio, Vincenzo Sforza, Nunzia Matrone, Floriana Morgillo, Carminia Maria Della Corte, Davide Ciardiello, Teresa Troiani, Stefania Napolitano, Valentina Belli, Pietro Paolo Vitiello, Claudia Cardone, and Giulia Martini

Abstract

Supplementary Table 1: Treatment with ALW-II-41-27 or cetuximab as single agents

Published
2023
Full Text
View/download PDF

38. Supplementary Methods from Epithelial-to-Mesenchymal Transition Promotes Tubulin Detyrosination and Microtentacles that Enhance Endothelial Engagement

Author

Stuart S. Martin, Jing Yang, Kimberly C. Tuttle, Olga B. Ioffe, Jennifer R. Yoon, Michele I. Vitolo, Eric M. Balzer, Edward H. Cho, Michael A. Matrone, and Rebecca A. Whipple

Abstract

Supplementary Methods from Epithelial-to-Mesenchymal Transition Promotes Tubulin Detyrosination and Microtentacles that Enhance Endothelial Engagement

Published
2023
Full Text
View/download PDF

40. Supplementary Figure 1 from Epithelial-to-Mesenchymal Transition Promotes Tubulin Detyrosination and Microtentacles that Enhance Endothelial Engagement

Author

Stuart S. Martin, Jing Yang, Kimberly C. Tuttle, Olga B. Ioffe, Jennifer R. Yoon, Michele I. Vitolo, Eric M. Balzer, Edward H. Cho, Michael A. Matrone, and Rebecca A. Whipple

Abstract

Supplementary Figure 1 from Epithelial-to-Mesenchymal Transition Promotes Tubulin Detyrosination and Microtentacles that Enhance Endothelial Engagement

Published
2023
Full Text
View/download PDF

43. Supplementary Figure Legends 1-5 from Epithelial-to-Mesenchymal Transition Promotes Tubulin Detyrosination and Microtentacles that Enhance Endothelial Engagement

Author

Stuart S. Martin, Jing Yang, Kimberly C. Tuttle, Olga B. Ioffe, Jennifer R. Yoon, Michele I. Vitolo, Eric M. Balzer, Edward H. Cho, Michael A. Matrone, and Rebecca A. Whipple

Abstract

Supplementary Figure Legends 1-5 from Epithelial-to-Mesenchymal Transition Promotes Tubulin Detyrosination and Microtentacles that Enhance Endothelial Engagement

Published
2023
Full Text
View/download PDF

47. Supplementary Figure 5 from Epithelial-to-Mesenchymal Transition Promotes Tubulin Detyrosination and Microtentacles that Enhance Endothelial Engagement

Author

Stuart S. Martin, Jing Yang, Kimberly C. Tuttle, Olga B. Ioffe, Jennifer R. Yoon, Michele I. Vitolo, Eric M. Balzer, Edward H. Cho, Michael A. Matrone, and Rebecca A. Whipple

Abstract

Supplementary Figure 5 from Epithelial-to-Mesenchymal Transition Promotes Tubulin Detyrosination and Microtentacles that Enhance Endothelial Engagement

Published
2023
Full Text
View/download PDF

48. Supplementary Figure 3 from Epithelial-to-Mesenchymal Transition Promotes Tubulin Detyrosination and Microtentacles that Enhance Endothelial Engagement

Author

Stuart S. Martin, Jing Yang, Kimberly C. Tuttle, Olga B. Ioffe, Jennifer R. Yoon, Michele I. Vitolo, Eric M. Balzer, Edward H. Cho, Michael A. Matrone, and Rebecca A. Whipple

Abstract

Supplementary Figure 3 from Epithelial-to-Mesenchymal Transition Promotes Tubulin Detyrosination and Microtentacles that Enhance Endothelial Engagement

Published
2023
Full Text
View/download PDF

50. Data from Vimentin Filaments Support Extension of Tubulin-Based Microtentacles in Detached Breast Tumor Cells

Author

Stuart S. Martin, Jennifer R. Yoon, Michael A. Matrone, Edward H. Cho, Eric M. Balzer, and Rebecca A. Whipple

Abstract

Solid tumor metastasis often involves detachment of epithelial carcinoma cells into the vasculature or lymphatics. However, most studies of cytoskeletal rearrangement in solid tumors focus on attached cells. In this study, we report for the first time that human breast tumor cells produce unique tubulin-based protrusions when detached from extracellular matrix. Tumor cell lines of high metastatic potential show significantly increased extension and frequency of microtubule protrusions, which we have termed tubulin microtentacles. Our previous studies in nontumorigenic mammary epithelial cells showed that such detachment-induced microtentacles are enriched in detyrosinated α-tubulin. However, amounts of detyrosinated tubulin were similar in breast tumor cell lines despite varying microtentacle levels. Because detyrosinated α-tubulin associates strongly with intermediate filament proteins, we examined the contribution of cytokeratin and vimentin filaments to tumor cell microtentacles. Increased microtentacle frequency and extension correlated strongly with loss of cytokeratin expression and up-regulation of vimentin, as is often observed during tumor progression. Moreover, vimentin filaments coaligned with microtentacles, whereas cytokeratin did not. Disruption of vimentin with PP1/PP2A-specific inhibitors significantly reduced microtentacles and inhibited cell reattachment to extracellular matrix. Furthermore, expression of a dominant-negative vimentin mutant disrupted endogenous vimentin filaments and significantly reduced microtentacles, providing specific genetic evidence that vimentin supports microtentacles. Our results define a novel model in which coordination of vimentin and detyrosinated microtubules provides structural support for the extensive microtentacles observed in detached tumor cells and a possible mechanism to promote successful metastatic spread. [Cancer Res 2008;68(14):5678–88]

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results